Profiling Siglec-7 and Siglec-9 ligands across the LuCaP PDX series: Implications for glyco-immune checkpoint inhibition in advanced prostate cancer
Ziqian Peng, Libby Blencoe, Kirsty Hodgson, Margarita Orozco‐Moreno, Lizhi Cao, Wayne Gatlin, Li Peng, James Broderick, Richard Beatson, Jennifer Munkley
The paper profiles Siglec-7 and Siglec-9 ligands across LuCaP PDX models and clinical specimens, showing lineage-independent glyco-immune checkpoint expression and model-dependent glycan remodelling under castration.
bioRxiv · Oct 19, 2026 · PreprintCancer Biology